Clinical Trials Logo
  1. Home
  2. Amphetamine-related Disorders
  3. NCT00267657
  4. Details
NCT00267657 Clinical Trial

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

Amphetamine-Related Disorders Clinical Trial

Official title:
Assessment of Interactions Between IV Methamphetamine and Reserpine

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT00267657
Other study ID # NIDA-CPU-0006-1
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received December 20, 2005
Last updated January 10, 2017
Start date January 2004
Est. completion date November 2004

Study information
Verified date December 2005
Source National Institute on Drug Abuse (NIDA)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

Description:

In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 30
Est. completion date November 2004
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 21 Years to 45 Years
Eligibility Inclusion Criteria:

- Please contact site for more details

Exclusion Criteria:

- Please contact site for more details

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Reserpine

Locations
Country Name City State
United States U of CA, San Francisco San Francisco California

Sponsors (1)
Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Craving
Primary Cardiovascular
Primary Subjective symptoms/Mood Effects
Primary CNS norepinephrine turnover
See also
  Status Clinical Trial Phase
Completed NCT02232789 - Abuse Liability and Human Pharmacology of Mephedrone Phase 1
Completed NCT01449565 - Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) Phase 2
Completed NCT00247572 - Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Phase 2
Active, not recruiting NCT00100074 - To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1 Phase 1
Active, not recruiting NCT00033072 - Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1 Phase 1
Recruiting NCT06145698 - Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD N/A
Completed NCT00990067 - Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Phase 1
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Recruiting NCT01899313 - A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence N/A
Active, not recruiting NCT00265278 - Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1 Phase 1
Active, not recruiting NCT00000350 - Effects of Stimulant Dependence on Human Striatal Dopamine System - 15 Phase 1
Active, not recruiting NCT00089440 - Assessment of Interactions Between Methamphetamine and Aripiprazole - 1 Phase 1
Active, not recruiting NCT00040040 - Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1 Phase 1
Completed NCT00040053 - Ondansetron for the Treatment of Methamphetamine Dependence - 1 Phase 2
Completed NCT00895804 - Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine) Phase 1
Recruiting NCT03902405 - Computerized Exercise to Alter Stimulant Approach Responses N/A
Recruiting NCT04982796 - Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder Phase 1/Phase 2
Completed NCT01386177 - Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA) Phase 1
Completed NCT01136278 - Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA) Phase 1
Completed NCT00069251 - Bupropion for the Treatment of Methamphetamine Dependence - 1 Phase 2